What is Syndax Pharmaceuticals's stock-based comp?

Syndax Pharmaceuticals (SNDX) reported stock-based comp of $12.05M in Q1 2026.

How has Syndax Pharmaceuticals's stock-based comp changed year-over-year?

Syndax Pharmaceuticals's stock-based comp increased by 16.1% year-over-year, from $10.38M to $12.05M.

What is the long-term trend for Syndax Pharmaceuticals's stock-based comp?

Over 4 years (2021 to 2025), Syndax Pharmaceuticals's stock-based comp has grown at a 37.4% compound annual growth rate (CAGR), from $13.32M to $47.5M.

Syndax Pharmaceuticals SNDX Stock-Based Comp

Stock-Based Comp at other companies

BiogenBIIB

——

SELLAS Life Sciences Group, Inc.SLS

——

Summit TherapeuticsSMMT

——

Jazz PharmaceuticalsJAZZ

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.77B+95.0%

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's stock-based comp?: Syndax Pharmaceuticals (SNDX) reported stock-based comp of $12.05M in Q1 2026.
How has Syndax Pharmaceuticals's stock-based comp changed year-over-year?: Syndax Pharmaceuticals's stock-based comp increased by 16.1% year-over-year, from $10.38M to $12.05M.
What is the long-term trend for Syndax Pharmaceuticals's stock-based comp?: Over 4 years (2021 to 2025), Syndax Pharmaceuticals's stock-based comp has grown at a 37.4% compound annual growth rate (CAGR), from $13.32M to $47.5M.